LINC02159 Promotes Non-small Cell Lung Cancer Progression Via ALYREF/YAP1 Signaling

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2023 Aug 3

PMID 37537569

Authors

Qiurong Yang

Maoye Wang

Jing Xu

Dan Yu

Yixin Li

YanKe Chen

Xiaoxin Zhang

Jiahui Zhang

Jianmei Gu

Xu Zhang

Affiliations

Soon will be listed here.

Abstract

Lung cancer is the leading cause of cancer-related deaths worldwide. Long non-coding RNAs (lncRNAs) have emerged as key regulators of cancer development and progression, and as promising biomarkers for the diagnosis and prognosis of cancer. In this study, we identified a new lncRNA (LINC02159) that was upregulated in the tumor tissues and serum of non-small cell lung cancer (NSCLC) patients. We demonstrated that knockdown of LINC02159 inhibited NSCLC cell proliferation, migration, and invasion, but induced cell apoptosis and cell cycle arrest in vitro and retarded tumor growth in vivo, while overexpression of LINC02159 led to the opposite effect. We discovered that LINC02159 was highly correlated with cancer growth and metastasis-related pathways by using transcriptomic analysis and that YAP1 was a potential target gene of LINC02159. Mechanistically, LINC02159 bound to the Aly/REF export factor (ALYREF) to enhance the stability of YAP1 messenger RNA (mRNA) via mC modification, which led to the overexpression of YAP1 and the activation of the Hippo and β-catenin signaling pathways in NSCLC cells. Rescue experiments showed that LINC01259 promoted NSCLC progression in a YAP1- and ALYREF-dependent manner. In conclusion, LINC02159 plays an oncogenic role in NSCLC progression by regulating ALYREF/YAP1 signaling, and it has the potential to be utilized as a diagnostic marker and therapeutic target for NSCLC.

Citing Articles

NSUN4 Facilitates the Activity of Oncogenic Protein CDC20 to Promote NSCLC Development by Mediating m5C Modification of CDC20 mRNA.

Li Z, Wu X Thorac Cancer. 2025; 16(5):e70023.

PMID: 40051202 PMC: 11885798. DOI: 10.1111/1759-7714.70023.

Epigenetic modifications in early stage lung cancer: pathogenesis, biomarkers, and early diagnosis.

Bi L, Wang X, Li J, Li W, Wang Z MedComm (2020). 2025; 6(3):e70080.

PMID: 39991629 PMC: 11843169. DOI: 10.1002/mco2.70080.

Biological functions of 5-methylcytosine RNA-binding proteins and their potential mechanisms in human cancers.

Zhao T, Zhang Z, Chen Z, Xu G, Wang Y, Wang F Front Oncol. 2025; 15:1534948.

PMID: 39990690 PMC: 11842269. DOI: 10.3389/fonc.2025.1534948.

Upregulation of TTYH3 by lncRNA LUCAT1 through interacting with ALYREF facilitates the metastasis in non-small cell lung cancer.

Fang F, Zhao M, Meng J, He J, Yang C, Wang C Cancer Biol Ther. 2025; 26(1):2464966.

PMID: 39930621 PMC: 11817527. DOI: 10.1080/15384047.2025.2464966.

YAP/TAZ-Hippo pathway mediates the tumorigenesis of various cancers through post-translational modification represented by ubiquitination.

Xu F, Li Z, Guan H, Ma J Cell Death Discov. 2025; 11(1):41.

PMID: 39900917 PMC: 11790847. DOI: 10.1038/s41420-025-02319-w.

References

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

Herbst R, Morgensztern D, Boshoff C . The biology and management of non-small cell lung cancer. Nature. 2018; 553(7689):446-454. DOI: 10.1038/nature25183. View

Yao R, Wang Y, Chen L . Cellular functions of long noncoding RNAs. Nat Cell Biol. 2019; 21(5):542-551. DOI: 10.1038/s41556-019-0311-8. View

Yap K, Li S, Munoz-Cabello A, Raguz S, Zeng L, Mujtaba S . Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell. 2010; 38(5):662-74. PMC: 2886305. DOI: 10.1016/j.molcel.2010.03.021. View

Gong C, Maquat L . lncRNAs transactivate STAU1-mediated mRNA decay by duplexing with 3' UTRs via Alu elements. Nature. 2011; 470(7333):284-8. PMC: 3073508. DOI: 10.1038/nature09701. View

Statello L, Guo C, Chen L, Huarte M . Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2020; 22(2):96-118. PMC: 7754182. DOI: 10.1038/s41580-020-00315-9. View

Priyanka P, Sharma M, Das S, Saxena S . The lncRNA HMS recruits RNA-binding protein HuR to stabilize the 3'-UTR of HOXC10 mRNA. J Biol Chem. 2021; 297(2):100997. PMC: 8363838. DOI: 10.1016/j.jbc.2021.100997. View

Huarte M . The emerging role of lncRNAs in cancer. Nat Med. 2015; 21(11):1253-61. DOI: 10.1038/nm.3981. View

Sun J, Xiong Y, Jiang K, Xin B, Jiang T, Wei R . Hypoxia-sensitive long noncoding RNA CASC15 promotes lung tumorigenesis by regulating the SOX4/β-catenin axis. J Exp Clin Cancer Res. 2021; 40(1):12. PMC: 7789733. DOI: 10.1186/s13046-020-01806-5. View

10.

Su H, Fan G, Huang J, Qiu X . LncRNA HOXC-AS3 promotes non-small-cell lung cancer growth and metastasis through upregulation of YBX1. Cell Death Dis. 2022; 13(4):307. PMC: 8986809. DOI: 10.1038/s41419-022-04723-x. View

11.

Li Y, Shen Y, Xie M, Wang B, Wang T, Zeng J . LncRNAs LCETRL3 and LCETRL4 at chromosome 4q12 diminish EGFR-TKIs efficiency in NSCLC through stabilizing TDP43 and EIF2S1. Signal Transduct Target Ther. 2022; 7(1):30. PMC: 8801511. DOI: 10.1038/s41392-021-00847-2. View

12.

Ma J, Zhang M, Yu J . Identification and Validation of Immune-Related Long Non-Coding RNA Signature for Predicting Immunotherapeutic Response and Prognosis in NSCLC Patients Treated With Immunotherapy. Front Oncol. 2022; 12:899925. PMC: 9289523. DOI: 10.3389/fonc.2022.899925. View

13.

Min L, Zhu T, Lv B, An T, Zhang Q, Shang Y . Exosomal LncRNA RP5-977B1 as a novel minimally invasive biomarker for diagnosis and prognosis in non-small cell lung cancer. Int J Clin Oncol. 2022; 27(6):1013-1024. PMC: 9120093. DOI: 10.1007/s10147-022-02129-5. View

14.

Chen X, Li A, Sun B, Yang Y, Han Y, Yuan X . 5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs. Nat Cell Biol. 2019; 21(8):978-990. DOI: 10.1038/s41556-019-0361-y. View

15.

Liu Y, Zhao Y, Wu R, Chen Y, Chen W, Liu Y . mRNA m5C controls adipogenesis by promoting CDKN1A mRNA export and translation. RNA Biol. 2021; 18(sup2):711-721. PMC: 8782175. DOI: 10.1080/15476286.2021.1980694. View

16.

Zhang Q, Liu F, Chen W, Miao H, Liang H, Liao Z . The role of RNA mC modification in cancer metastasis. Int J Biol Sci. 2021; 17(13):3369-3380. PMC: 8416729. DOI: 10.7150/ijbs.61439. View

17.

Ma Y, Yang J, Ji T, Wen F . Identification of a novel m5C/m6A-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma. Front Genet. 2022; 13:990623. PMC: 9561349. DOI: 10.3389/fgene.2022.990623. View

18.

Yu W, Zhang C, Wang Y, Tian X, Miao Y, Meng F . YAP 5-methylcytosine modification increases its mRNA stability and promotes the transcription of exosome secretion-related genes in lung adenocarcinoma. Cancer Gene Ther. 2022; 30(1):149-162. PMC: 9842506. DOI: 10.1038/s41417-022-00533-7. View

19.

Gibault F, Sturbaut M, Bailly F, Melnyk P, Cotelle P . Targeting Transcriptional Enhanced Associate Domains (TEADs). J Med Chem. 2017; 61(12):5057-5072. DOI: 10.1021/acs.jmedchem.7b00879. View

20.

Tsai B, Hoverter N, Waterman M . Blending hippo and WNT: sharing messengers and regulation. Cell. 2012; 151(7):1401-3. DOI: 10.1016/j.cell.2012.12.007. View